Notification That All Shares of Hakushindo Pharmaceutical Have Been Acquired by Shinkowa Pharmaceutical Co., Ltd., the First Company in the World to Sell NMN Compound Supplements

20-Mar-2018 Intellasia | BusinessWire | 10:30 PM Print This Post

Toward the Realization of Academic-industry Integration For True
Anti-aging Medicine (Rejuvenation Research)!

TOKYO–(BUSINESS WIRE)–Shinkowa Pharmaceutical Co., Ltd., (Head Office: Chuo-ku, Tokyo, CEO:
Megumi Tanaka) whose goal is to achieve productive aging around the
world, has acquired all shares of Hakushindo Pharmaceutical Co., Ltd.
(head office: Shinjuku-ku, Tokyo, CEO: Daizo Shimamura), an organization
that provides research funds to the Project Research Center For Clinical
Trials and Preventative Medicine at the Hiroshima University Graduate
School of Biomedical & Health Sciences, the organization that carried
out the world’s first clinical study (24 weeks) of the long-term oral
intake of NMN (β nicotinamide mononucleotide).

Clinical studies on oral NMN intake are currently underway at the
Hiroshima University Graduate School of Biomedical & Health Sciences:
Project Research Center For Clinical Trials and Preventative Medicine.
there are no plans for public disclosure of the clinical research
UMIN trial ID: UMIN000025739

Based on the results of these clinical studies at Hiroshima University
Graduate School of Biomedical & Health Sciences: Project Research Center
For Clinical Trials and Preventative Medicine, Shinkowa Pharmaceutical
Co., Ltd. intends to create products based on the newly discovered
effects of NMN, and to continue clinical research related to the
possibilities that have emerged in relation to these new effects.
we do not plan to publicly announce the results of this clinical study,
we do intend to actively disclose the information free of charge to
researchers and organizations involved in NMN research.

In September 2015, Shinkowa Pharmaceuticals commissioned clinical trial
contractor DRC Co., Ltd. to implement the world’s first human clinical
trial of NMN. The trial has been completed and we have already received
the clinical results.
By acquiring the shares of Hakushindo
Pharmaceutical Co., Ltd., we will further build up the clinical trial
results database of the Hiroshima University Graduate School of
Biomedical & Health Sciences: Project Research Center For Clinical
Trials and Preventative Medicine.

About Clinical trial by DRC Co., Ltd.

Clinical trial name: Study on the Lipid Improvement Effects of Ingesting
Foods and Compounds Containing Resveratrol and Nicotinamide

Trial plan number: F_1507092
Version 1 creation date: September 1,
2015 Version No.: Version 1
Ethics Review Committee approval date:
September 4, 2015

In addition, although Shinkowa Pharmaceuticals is currently purchasing
NMN from a manufacturer, we have already signed contracts for the
provision of technology to manufacture NMN, and are aiming to establish
and operate what will become Japan’s 2nd ever domestic NMN manufacturing
facility (production volume: about 3 tons/year).
We believe that
this factory operation will allow us to significantly lower the cost of
the products we currently sell, as well as new products.

In the future, in regard to the cosmetic products we currently sell, we
plan to confirm increased NMN and NADH both in the skin and
subcutaneously, and confirm mitochondrial activity. We also have plans
to develop new pet supplement products.

We are also considering a project to provide ongoing support for free or
partially discounted products to people with health problems for which
the effectiveness of NMN has been confirmed.

In order to realize productive aging worldwide and continue to innovate
and contribute, we have also begun preparations to increase our capital
through a third-party share allocation. The funds raised will be used
for capital investments related to the establishment of an NMN
manufacturing facility (factory construction costs, employment
expenses), as well as the costs of carrying out numerous human clinical
trials in order to request the examination of several patents we have
(We are currently recruiting engineers for our NMN factory.)
also intend to seek business tie-ups with companies that are actively
looking to invest in the NMN business and the field of productive aging.

“Shinkowa Pharmaceutical sincerely aims to achieve productive aging
worldwide, based on scientific evidence.”
We are the company
that will achieve productive aging worldwide by advancing biomedical

Company profile
Company name: Shinkowa Pharmaceutical Co., Ltd.
Megumi Tanaka
Location: 2-30-11 Shinkawa, Chuo-ku, Tokyo
description: Health food and cosmetics distribution and trade


For inquiries related to this press release
Shinkowa Pharmaceutical
Co., Ltd.
Daizo Shimamura, +81-3-5403-6393
[email protected]
* Please make all inquiries by email.


Category: BusinessWire, PRAsia

Print This Post

Comments are closed.